

Paving the way to a Cancer-Free World



Korean Cancer Study Group

KCSG 2022

Brief Annual Report



Dedicated
to the best cancer clinical trials

Contact Info

E-mail kcsq@kcsq.org

Website www.kcsq.org

Address #1501, 49, Ahasan-ro, Seongdong-gu, Seoul 04790, Rep. of KOREA



Paving the Way to a Cancer-free World

Korean Cancer Study Group (KCSG) is the nation’s leader in multi-institutional clinical trials for cancer treatment.

Since our establishment in 1998, KCSG has been dedicated to the advancement of clinical and translational cancer research through multi-institutional clinical trials in Korea.

2022 KEY FIGURES




GOAL

- To design and conduct practice changing clinical trials
- To promote international collaborative cancer research
- To optimize multidisciplinary team science in cancer research
- To implement education and training on cancer treatments and clinical trials
- To improve public access to cancer clinical trials


VISION

Paving the Way to a Cancer-free World


RESEARCH FIELD




MEMEBERSHIP




800+ members from 120 hospitals and institutions in Korea



Clinical oncologists across all oncology disciplines




Well-trained healthcare professionals including CRAs, CRCs, CRPs, and members of CRO




Highly interconnected national network for efficient global clinical trials

KOREAN CANCER STUDY GROUP Member


Total
824













ORGANIZATION



OUR HISTORY




LANDMARK TRIALS

 Hepatobiliary & Pancreatic Cancer	<p>KCSG HB19-14 / The Lancet Gastroenterology & Hepatology. (Published Online October 31, 2022)</p> <p>Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)</p>	 Stomach Cancer	<p>KCSG ST19-16 / Ther Adv Med Oncol. 2021 Sep 18;13:17588359211042812</p> <p>Ramucirumab plus paclitaxel as secondline treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)</p>
 Colorectal Cancer	<p>KCSG CO09-07 / J Clin Oncol. 2022 Jun 30;JCO2102962.</p> <p>Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07</p>	 Stomach Cancer	<p>KCSG ST19-16 / Gastric Cancer. 2022 May;25(3):609-618.</p> <p>Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)</p>
 Head & Neck and Esophageal Cancer	<p>KCSG HN17-11 / Clin Cancer Res. 2022 July 2022</p> <p>A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)</p>	 Breast Cancer	<p>KCSG BR18-23 / JAMA Oncol. 2022 Jul 7.</p> <p>Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial</p>
 Genitourinary Cancer	<p>KCSG GU10-16 / Eur J Cancer. 2020 Mar;127:183-190</p> <p>Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).</p>	 Lung Cancer	<p>KCSG LU20-11 / Cancer. 2022 Feb 15;128(4):778-787.</p> <p>Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)</p>
 Palliative Care	<p>KCSG PC17-01 / Support Care Cancer. 2022 May 27.</p> <p>Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer</p>	 Others	<p>Cancer Res Treat. 2022 Jan;54(1):1-9</p> <p>Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group</p>

WHAT WE DO




KCSG'S CLINICAL TRIAL PROCEDURE



DATA CENTER



Data Center Is a clinical operation organization in KCSG.
We provide high-quality clinical operational services to study sponsors, complying with ICH guidelines, Korean GCP and relevant regulations.




RESEARCH ACCOMPLISHMENTS

24 years of paving the way
to a cancer-free world



256 clinical research
since 1998










Publication



ONGOING TRIALS

Disease Committee	Phase	Study No.	Study Name
 Breast Cancer	Ib&II	KCSG BR18-10	Phase IB & II study of Ribociclib with Trastuzumab plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
	II	KCSG BR18-13	Phase II Study of Trastuzumab plus Gedatolisib in Patients with HER-2 Positive Metastatic Breast Cancer Who Progressed after 2 or more HER-2 directed Chemotherapy
	II	KCSG BR18-21	Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab plus capecitabine Adjuvant Therapy compared to Capecitabine monotherapy for Triple Receptor-Negative Breast Cancer with Residual Invasive Cancer after Neoadjuvant Chemotherapy.
	II	KCSG BR19-03	Randomized, Open label, Multi-Center, Phase II Trial of Eribulin with or without SB3 (Trastuzumab-biosimilar) in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens
	II	KCSG BR19-13	Single-arm Phase II Study of Palbociclib Plus Endocrine Therapy in Patients With High Risk ER-positive/HER2-negative T1-2N0-1 Early Breast Cancer Incorporating GenesWell™ BCT
	II	KCSG BR19-21	Phase II Study of Abemaciclib plus Trastuzumab biosimilar(Herzuma®) ± Fulvestrant in Patients with HER2 Positive Metastatic Breast Cancer in Brain who Progressed after HER2 directed Chemotherapy
	II	KCSG BR21-08	Randomized open-label multicenter phase II trial comparing first-line Olaparib versus CDK4/6i plus endocrine therapy in patients with gBRCAmut-associated HR(+)/HER2(-) recurrent unresectable and/or metastatic breast cancer (OPERA trial)
	II	KCSG BR21-09	Randomized Phase II Study of Talazoparib Versus Talazoparib Plus Atezolizumab After Palbociclib Combination Endocrine Therapy for Patients With Premenopausal HR+/HER2- Metastatic Breast Cancer Harboring HRD Scar
	II	KCSG BR21-10	A randomized phase II clinical trial of talazoparib maintenance therapy in triple-negative breast cancer patients who showed platinum-sensitivity on first- or second-line platinum-based chemotherapy
	OS	KCSG BR21-15	Nationwide real-world practice pattern and clinical data of palbociclib in Hormone-receptor positive, HER2-negative metastatic breast cancer patients
	II	KCSG BR20-16	Phase II trial of pembrolizumab and paclitaxel in hormone receptor-positive, hyperMUTATted metastatic breast cancer Identified by whole exOme sequeNcing ('MUTATION2')
	II	KCSG BR21-23	De-escalation of adjuvant chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer subjects who achieved pathological complete response after neoadjuvant chemotherapy and dual HER2-blockade.
 Colorectal Cancer	NA	KCSG CO15-07	Pattern of use of Bevacizumab or Cetuximab in patients with metastatic colorectal cancer when added to FOLFIRI regimen as first-line treatment;multi-centre, registry study
	II	KCSG CO19-18	A randomized, open-label, multicenter phase II study of bevacizumab, infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (A-FOLFOXIRI) compared with bevacizumab, infusional fluorouracil, leucovorin, and irinotecan/oxaliplatin (A-FOLFIRI/FOLFOX) as first-line treatment for metastatic right-sided colon cancer
	Ib&II	KCSG CO21-04	A phase Ib/II, open label, single arm study to assess efficacy and safety of alpelisib and capecitabine in patients with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies

Disease Committee	Phase	Study No.	Study Name
 Colorectal Cancer	OS	KCSG CO22-12	Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (CLAUDIA Colon Cancer) Part 1: Prospective Observational Study of ctDNA Monitoring During Adjuvant Chemotherapy in Stage II-III Colon Cancer Part 2: A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients with Positive MRD during Adjuvant Chemotherapy
 Genitourinary Cancer	III	KCSG GU16-05	A Prospective Randomized Phase III Trial of Maintenance Pemetrexed versus Observation in Patients with Recurrent or Metastatic Urothelial Carcinoma who completed first line platinum-based chemotherapy without disease progression
	II	KCSG GU20-03	A Multicenter Prospective Phase II Study of modified FOLFIRINOX for 1st line treatment for advanced urachus cancer (ULTIMA)
	NA	KCSG GU20-07	Multicenter retrospective evaluation of adherence to treatment guidelines of germ cell tumor and implication of treatment outcome
	NA	KCSG GU20-18	Predictive clinical factors for Docetaxel-rechallenge in castration-resistant prostate cancer patients treated with docetaxel in hormone-sensitive setting
	NA	KCSG GU20-19	Molecular epidemiology study on germ line mutation in patients with metastatic prostate cancer
	II	KCSG GU21-02	CAbozanTinib As Subsequent therapy to an Immune checkpoint inhibitor-based therapy in renAl cell carcinoma, phase 2, multicenter, open-label, interventional study (AT ASIA)
	II	KCSG GU21-14	A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy (ACCOMPLISH)
	NA	KCSG GU22-13	Multicenter retrospective study of REal-world feasibility and biomarker exploration of 1st-line NivOlumab and Ipilimumab in patients with advanced renal cell carcinoma (RCC) : RENOIR study
	OS	KCSG GU22-14	A retrospective study on the efficacy and safety of immunotherapeutics in HLRCC-associated RCC
 Gynecologic Cancer	Ib&II	KCSG GY20-10	Phase 1b/2, single arm clinical trial to evaluate the safety and activity of oregovomab and bevacizumab, paclitaxel carboplatin as a combinatorial strategy in subjects with BRCA-wild type platinum sensitive recurrent ovarian cancer
	II	KCSG GY22-08	Single-arm phase II study of bevacizumab plus modified FOLFIRINOX chemotherapy in ovarian, fallopian tube, or primary peritoneal mucinous carcinoma
 Head & Neck and Esophageal Cancer	II	KCSG HN18-07	A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic Pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma (SCC)
	II	KCSG HN19-09	A randomized phase II study of consolidation pembrolizumab therapy after chemoradiotherapy in locally advanced nasopharyngeal carcinoma
	III	KCSG HN19-23	Randomized Phase II trial of a PD-1 inhibitor INCMGA00012 as consolidation therapy after definitive concurrent chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma (RHAPSODY)
	NA	KCSG HNE20-20	Multi-center umbrella trial based on genetic analysis in rare/refractory head and neck cancer (TRIUMPH2): part 2 salivary gland cancer master protocol
	NA	KCSG HNE21-25	A Registry study of Larotrectinib chemotherapy in patients with NTRK fusion positive recurrent salivary gland cancer as second-line treatment

Disease Committee	Phase	Study No.	Study Name
 Head & Neck and Esophageal Cancer	II	KCSG HNE21-26	Phase II study of darolutamide combined with chemotherapy in patients with recurrent and/or metastatic salivary gland cancer
	II	KCSG HNE21-27	A phase II study of axitinib and chemotherapy in patients with recurred or metastatic salivary gland cancer
	II	KCSG HNE21-24	An open label, single arm, multicenter phase II study of AST-301 in patients with advanced or metastatic salivary gland tumor with HER2 overexpression
 Hepatobiliary & Pancreatic Cancer	III	KCSG HB20-14	A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy with Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer
 Lung Cancer	II	KCSG LU15-04	Phase II trial of paclitaxel (T) vs Irinotecan(I) in patients with previously Etoposide/ platinum (EP) treated, extensive disease (ED) small cell lung cancer (SCLC) as 2nd line chemotherapy
	III	KCSG LU15-12	A phase III, randomized, multi-center study to determine the efficacy of the intercalating combination treatment of chemotherapy and gefitinib or chemotherapy as adjuvant treatment in NSCLC with common EGFR mutations.
	NA	KCSG LU15-14	Identification of Genomic Landscape of Korean Patients with Lung Cancer through Establishment of Database for Molecular Genotyping
	II	KCSG LU19-24	Phase II study of durvalumab, doxorub icin, and ifosfamide in pulmonary sarcomatoid carcinoma
	II	KCSG LU21-11	A multicentre two-arm, phase II trial assessing the safety and efficacy of first-line lazertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancer
	II	KCSG LU21-16	Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial
	II	KCSG LU21-17	Phase II Trial of Lazertinib and Pemetrexed/Carboplatin Combination in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Metastatic Non-Small Cell Lung Cancer with Asymptomatic or Mild Symptomatic Brain Metastases After Failure of Osimertinib
	NA	KCSG LU22-01	Lazertinib real-world observational study of in pre-treated EGFR T790M mutant with advanced non-small cell lung cancer (Lazer Sword)
	NA	KCSG LY17-08	Clinical outcomes of R-miniCHOP in elderly patients older than 80 years with diffuse large B cell lymphoma: registry
 Lymphoma	II	KCSG LY22-07	Phase II study of tislelizumab plus pemetrexed in patients with relapsed or refractory primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS)
	NA	KCSG LY18-01	Clinical outcomes and prognostic factors in patients with advanced-stage extranodal NK/T-cell lymphoma: Korean multicenter retrospective study
	OS	KCSG LY22-15	Clinico-genetic features of Korean patients with Erdheim-Chester disease
 Palliative Care	II	KCSG PC20-12	Efficacy and safety of transdermal buprenorphine patch in cancer patients who are physically dependent on opioids
	NA	KCSG PC22-10	Benefits of life review therapy for progressive cancer patients
	III	KCSG PC22-11	COmparisoN of prophylactic effects for Chemotherapy Induced neutropenia between SamE-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myelosuppressive agent: A randomized phase III clinical trial (CONCISE trial)

Disease Committee	Phase	Study No.	Study Name
 Rare Cancer	NA	KCSG UN18-09	Clinicopathologic characterization of the rare cancer in Korea: multi-center retrospective study
	NA	KCSG RC22-02	The genomic landscape of adult sarcoma in Korea
 Stomach Cancer	III	KCSG ST14-05	Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer
	III	KCSG ST15-08	A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) who Received Radical Resection
	III	KCSG ST17-20	A multicenter, randomized, open label, phase III trial to evaluate the efficacy and safety of the combination of S-1, oxaliplatin and irinotecan in comparison to the combination of S-1 and cisplatin as first-line treatment in patients with metastatic or relapsed gastric cancer
	II	KCSG ST19-11	Phase 2 study of paclitaxel plus anti-EGFR as a second-line therapy for gastric and gastroesophageal junction adenocarcinomas
	NA	KCSG ST20-04	The Master Protocol for Cancer Genomic Screening in Patients with Advanced Gastric Cancer
	III	KCSG ST21-05	A randomized phase 3 clinical trial investigating optimal duration of oxaliplatin administration in postoperative XELOX (oxaliplatin + capecitabine) adjuvant chemotherapy for the patients with stage II/III gastric cancer
	II	KCSG ST21-12	Vactosertib in combination with durvalumab (MEDI4736) in patients with gastric cancer
	III	KCSG ST22-03	Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative Chemotherapy
	OS	KCSG ST22-06	Comparison of 3rd line immune checkpoint inhibitors to irinotecan-based chemotherapy in patient with refractory to paclitaxel plus ramucirumab : multi-center, observational study
	Ib&II	KCSG ST21-22	A phase 1b/2 study of tepotinib in combination with paclitaxel in patients with MET amplified or MET exon 14 altered advanced gastric and gastroesophageal junction carcinoma
	II	KCSG ST21-28	A phase II study of rivoceranib in combination with paclitaxel in patients with advanced gastric and gastroesophageal junction carcinoma
	II	KCSG AL20-17	An Open-Label, Multi-Center, Phase II Basket Trial to Evaluate Safety and Efficacy of Neratinib, An Irreversible Tyrosine Kinases Inhibitor of EGFR, ERBB2 and ERBB4 Receptors and Trastuzumab biosimilar (Herzuma®) in Patients with HER2 Mutated Advanced Solid Cancers
 Others	OS	KCSG AL21-13	Establishment of a geriatric assessment based multidisciplinary team approach on hospitalized older patients with advanced solid cancer: a multicenter randomized clinical trial
	OS	KCSG AL22-09	KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS) II
	II	KCSG AL22-16	A phase II clinical trial of Bevacizumab plus eRlotinib in patientS with advanced cancer having genetic alterations in Krebs cycle (BRISK)
	III	KCSG AL22-17	Prospective, multicenter, randomized phase 3 trial of high dose IV iron in combination of erythrocytosis stimulating agents in chemotherapy induced anemia with functional iron deficiency

GLOBAL COOPERATIVE ACTIVITIES

Cooperative Group	Study No.	Study Name
TRIO	TRIO033	A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAL with Ribociclib [LEE011]: NATALEE).
TRIO	TRIO039	A Phase 1b Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours
TRIO	TRIO041	A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of regorafenib in combination with nivolumab versus transarterial chemoembolization (TACE) for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria
TRIO	TRIO045	A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer
TRIO	TRIO051	A phase 1, first in human, dose-escalation study of TORL-2-307-MAB in participants with advanced cancer
TRIO	TRIO052	A phase 1, first in human, dose-escalation study of TORL-2-307-ADC in participants with advanced cancer
BIG	DECRESCENDO	De-escalation of adjuvant chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer subjects who achieved pathological complete response after neoadjuvant chemotherapy and dual HER2-blockade.
BIG	ALEXANDRA IMpason030	A phase III, multicentre, randomised, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy vs. chemotherapy alone in patients with operable triple-negative breast cancer (TNBC)



PUBLICATION IN 2022

<p>Breast Cancer Committee</p> <p>KCSG BR16-09 • PMID: 35344650 Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09) <i>Cancer Res Treat.</i> 2022 Mar 24. Online ahead of print.</p> <p>KCSG BR18-23 • PMID: 35797012 Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial <i>JAMA Oncol.</i> 2022 Sep 1;8(9):1271-1277.</p> <p>KCSG BR18-14 • PMID: 36029565 Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) <i>Breast.</i> 2022 Oct;65:172-178</p> <p>KCSG BR19-15/ST19-16 • PMID: 36339930 Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group <i>Ther Adv Med Oncol.</i> 2022 Nov 2;14:17588359221132628.</p> <p>KCSG BR07-03 • PMID: 36397238 A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) <i>Cancer Res Treat.</i> 2022 Nov 8.</p>	<p>Hepatobiliary & Pancreatic Cancer Committee</p> <p>KCSG HB19-14 • PMID: 36328033 Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14) <i>Lancet Gastroenterol Hepatol.</i> 2022 Oct 31. Online ahead of print.</p> <p>Lung Cancer Committee</p> <p>KCSG LU20-11 • PMID: 34705268 Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11) <i>Cancer.</i> 2022 Feb 15;128(4):778-787.</p> <p>KCSG LU19-22 • PMID: 35958320 Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 <i>Transl Lung Cancer Res.</i> 2022 Jul;11(7):1369-1379</p> <p>KCSG LU17-21 • PMID: 36307042 A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) <i>J Thorac Oncol.</i> 2022 Oct 25;S1556-0864(22)01858-5.</p> <p>KCSG LU21-11 • PMID: 36002368 A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11) <i>Clin Lung Cancer.</i> 2022 Dec;23(8):e536-e539.</p> <p>Palliative Care Committee</p> <p>KCSG PC17-01 • PMID: 35622149 Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer <i>Support Care Cancer.</i> 2022 Sep;30(9):7431-7438.</p> <p>KCSG PC21-20 • PMID: 36596728 Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20) <i>Cancer Res Treat.</i> 2022 Dec 27.</p> <p>Stomach Cancer Committee</p> <p>KCSG ST19-16 • PMID: 35015188 Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) <i>Gastric Cancer.</i> 2022 May;25(3):609-618.</p> <p>Others</p> <p>KPMNG • PMID: 34902959 Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group <i>Cancer Res Treat.</i> 2022 Jan;54(1):1-9.</p>
--	--